SAT-312 Beta-Arrestin 2 Is Required for Dopamine Receptor Type 2 Inhibitory Effects on Akt Phosphorylation and Cell Proliferation in Pituitary Tumors

Dopamine receptor type 2 (DRD2) agonists are the first-choice treatment for PRL-secreting pituitary tumors but are poorly effective in non-functioning pituitary neuroendocrine tumors (NF-PitNETs). DRD2 reduces AKT phosphorylation in lactotrophs, but no data are available in NF-PitNETs. DRD2 effects...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Endocr Soc
Egile Nagusiak: Mangili, Federica, Giardino, Elena, Treppiedi, Donatella, Barbieri, Anna Maria, Catalano, Rosa, Locatelli, Marco, Lania, Andrea G, Spada, Anna, Arosio, Maura, Mantovani, Giovanna, Peverelli, Erika
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2020
Gaiak:
Neuroendocrinology and Pituitary
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7209574/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.503
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak